不稳定型心绞痛与非ST段抬高型心肌梗死的发生率及结局比较
两项前瞻性多中心诊断研究(APACE和High-STEACS)纳入急诊急性胸痛患者,由两名独立心内科医生使用高敏肌钙蛋白等全部临床信息中心裁定诊断。UA发生率低于NSTEMI,30天和1年全因死亡率显著低于NSTEMI且与非心源性胸痛相似,但未来非致死性心肌梗死发生率与NSTEMI相当且高于非心源性胸痛。
要点
- UA发生率低于NSTEMI,APACE为8.9% vs 15.1%,High-STEACS为2.8% vs 13.4%。
- UA的30天和1年全因死亡率显著低于NSTEMI,且与非心源性胸痛相似。
- UA未来非致死性心肌梗死发生率与NSTEMI相当,高于非心源性胸痛。
核心结论
- UA相对发生率与死亡率显著低于NSTEMI,但未来非致死性心肌梗死发生率与NSTEMI相似。
研究设计与样本
- 两项独立前瞻性多中心诊断研究(APACE和High-STEACS),纳入急诊急性胸部不适患者,共8992例,在11个中心入组。
- 最终诊断由两名独立心内科医生使用包括连续高敏肌钙蛋白测量在内的全部临床信息中心裁定。
- 评估30天和1年的全因死亡及未来非致死性心肌梗死。
主要发现
- UA裁定比例在APACE为8.9%(95%CI 8.0-9.7),High-STEACS为2.8%(95%CI 2.3-3.3);NSTEMI分别为15.1%(95%CI 14.0-16.2)和13.4%(95%CI 12.4-14.3)。
- UA患者中既往冠心病比例在APACE为73%,High-STEACS为76%。
- 30天全因死亡率UA vs NSTEMI:APACE 0.5% vs 3.7%(p=0.002),High-STEACS 0.7% vs 7.4%(p=0.004)。
- 1年全因死亡率UA vs NSTEMI:APACE 3.3%(95%CI 1.2-5.3)vs 10.4%(95%CI 7.9-12.9),High-STEACS 5.1%(95%CI 0.7-9.5)vs 22.9%(95%CI 19.3-26.4),UA与非心源性胸痛相似。
- 未来非致死性心肌梗死:APACE中UA为11.2%(95%CI 7.8-14.6),NSTEMI为7.9%(95%CI 5.7-10.2),非心源性胸痛为0.6%(95%CI 0.2-1.0)。
临床怎么用
- UA患者死亡率低于NSTEMI,但未来非致死性心肌梗死风险与NSTEMI相当,需重视二级预防和随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Assess the relative incidence and compare characteristics and outcome of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI). DESIGN: Two independent prospective multicentre diagnostic studies (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE] and High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome [High-STEACS]) enrolling patients with acute chest discomfort presenting to the emergency department. Central adjudication of the final diagnosis was done by two independent cardiologists using all clinical information including serial measurements of high-sensitivity cardiac troponin (hs-cTn). All-cause death and future non-fatal MI were assessed at 30 days and 1 year. RESULTS: 8992 patients were enrolled at 11 centres. UA was adjudicated in 8.9%(95% CI 8.0 to 9.7) and 2.8% (95% CI 2.3 to 3.3) patients in APACE and High-STEACS, respectively, and NSTEMI in 15.1% (95% CI 14.0 to 16.2) and 13.4% (95% CI 12.4 to 14.3). Coronary artery disease was pre-existing in 73% and 76% of patients with UA. At 30 days, all-cause mortality in UA was substantially lower as compared with NSTEMI (0.5% vs 3.7%, p=0.002 in APACE, 0.7% vs 7.4%, p=0.004 in High-STEACS). Similarly, at 1 year in UA all-cause mortality was 3.3% (95% CI 1.2 to 5.3) vs 10.4% (95% CI 7.9 to 12.9) in APACE, and 5.1% (95% CI 0.7 to 9.5) vs 22.9% (95% CI 19.3 to 26.4) in High-STEACS, and similar to non-cardiac chest pain (NCCP). In contrast, future non-fatal MI in APACE was comparable in UA and NSTEMI (11.2%, 95% CI 7.8 to 14.6 and 7.9%, 95% CI 5.7 to 10.2), and higher than in NCCP (0.6%, 95% CI 0.2 to 1.0). CONCLUSIONS: The relative incidence and mortality of UA is substantially lower than that of NSTEMI, while the rate of future non-fatal MI is similar.
引用
- Puelacher C, Gugala M, Adamson PD, et al. Incidence and outcomes of unstable angina compared with non-ST-elevation myocardial infarction. Heart. 2019. PMID: 31018955. doi:10.1136/heartjnl-2018-314305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。